Updated:
Myeloma Investment Fund
The Myeloma Investment Fund is the first and only mission-driven venture philanthropy fund focused on accelerating a cure for multiple myeloma.
Myeloma Investment Fund
The Myeloma Investment Fund is the first and only mission-driven venture philanthropy fund focused on accelerating a cure for multiple myeloma.
General information
Firm type
Venture Philanthropy
Year founded
2019
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Norwalk
Corporate office
383 Main Avenue, 7th Floor, Norwalk, CT 06851, United States
Sector focus
Frequently asked questions
How is the Myeloma Investment Fund funded and who provides the capital?
The Myeloma Investment Fund is supported entirely by philanthropic donations. It operates as a wholly owned subsidiary of the Multiple Myeloma Research Foundation (MMRF), which has raised over $600 million for research since its inception, per the MIF website.
What happens to profits when a portfolio company exits or goes public?
All financial returns are reinvested back into the fund to support the development of future myeloma therapies. This perpetual recycling structure is a stated commitment of MIF's evergreen venture-philanthropy model, according to the firm's website.
Does the Myeloma Investment Fund invest in companies working on cancers beyond multiple myeloma?
Some portfolio companies pursue additional indications, but MIF's investment thesis is singularly focused on accelerating therapies and technologies for multiple myeloma. For example, Opna Bio's lead asset OPN-6602 is currently in a Phase 1 trial specifically for myeloma patients.
How does MIF source its deals differently from a standard biotech venture capital firm?
MIF leverages the Multiple Myeloma Research Foundation's deep integration in myeloma research — including nearly 100 clinical trials and over two decades of academic and industry partnerships — to identify companies where capital and strategic guidance can directly translate laboratory findings into clinical assets.
How is the Myeloma Investment Fund related to the Multiple Myeloma Research Foundation?
MIF is a wholly owned subsidiary of the MMRF, the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. The foundation has helped bring 15 FDA-approved therapies to market and opened nearly 100 clinical trials.
What stage of companies does the Myeloma Investment Fund invest in?
MIF invests in early-stage, venture-backed biotech companies, often at the preclinical or Phase 1 clinical trial stage. The portfolio includes companies like Telo Therapeutics, which is raising a Series A to advance its small molecule to an IND filing, and preclinical-stage Dynamic Cell Therapies.
Does the Myeloma Investment Fund lead rounds or participate alongside other venture firms?
The firm's investment approach combines financial support with scientific and strategic guidance through the MMRF network. Publicly available materials do not specify whether MIF leads or follows in syndicated rounds, but its portfolio companies include those backed by Avalon BioVentures (Fortis Therapeutics) and Dana-Farber Cancer Institute-derived spinouts (Dynamic Cell Therapies).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: